Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 35INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Chemotherapy 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Cisplatin 5Fluorouracil 4Capecitabine 4tislelizumab 2Radiation 2Gemcitabine 2toripalimab 1temoporfin 1nimotuzumab 1fludarabine 1Taxes 1Radiotherapy, Intensity-Modulated 1Maintenance Chemotherapy 1Drug Therapy 1Cyclophosphamide 1Cell Count 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Nasopharyngeal Carcinoma × toripalimab × Clear all
NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Fujian Cancer Hospital

Phase 2 Unknown
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡